Brought to you by 
Forest licenses Novexel's NXL104 for use with ceftaroline
27 Oct 2020
Executive Summary
Forest Laboratories has licensed exclusive North American rights to develop, manufacture, and commercialize Novexel SA's intravenous beta lactamase inhibitor NXL104 in combination with its own ceftaroline.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Forest licenses Novexel's NXL104 for use with ceftaroline
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice